Abstract 2839
Background
Obesity carries a high risk of breast cancer with worse treatment outcome. Different molecular subtype and prognostic factors are linked to high body mass index (BMI) and affects overall and progression-free survival.
Methods
All 950 breast cancer patients presented to kasr Alainy oncology center (NEMROCK) from 2004 - 2014 at Al kasr alainy oncology center (NEMROCK) were followed up with a median period of 4.2years till Dec 2018. The body mass index (BMI) was assessed at diagnosis in 760 female patients. Disease-free survival (DFS) and overall survival (OS) were assessed and compared between three groups: non-obese (BMI <30), obese (BMI 30-34.9) and severely obese (BMI >40).
Results
The mean age was 50.1 years with Obesity in 63.29% of cases (23.82% and 39.47% in obese and severely obese respectively). Significant correlations between non-obese and severely obese with age (52 vs.48 years, p < 0.001), menopausal status (31.3 vs.46.9%, p < 0.001), molecular types (non- luminal; 25 vs. 50% p < 0.011), Her2 status (44.4 vs. 27.2%, p = 0.014) and hormonal therapy (Tamoxifen alone, 44.3 vs. 30.4%, p = 0.001). Mean Overall survival(OS) was significantly better in non-obese groups compared to obese and severely obese (102.5, 80, 88months, P=value 0.019), with no impact on DFS (p = 0.40).In multivariate analysis, lymph node stage (p < 0.001; OR: 1; 95% CI: 0.07-0.46), BMI (p = 0.001; OR: 1; 95% CI: 0.14-0.61), and hormonal treatment tamoxifen alone(p = 0.001; OR: 1; 95%CI: 1.4-16.4) remained significantly associated with OS.
Conclusions
severe obesity (BMI >40) have worse overall survival with no impact on disease free survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).
Presenter: Kanan Alshammari
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract